{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T21:45:59Z","timestamp":1788385559198,"version":"build-2803163510"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T00:00:00Z","timestamp":1754524800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000065","name":"U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["NS003130"],"award-info":[{"award-number":["NS003130"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000065","name":"U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke","doi-asserted-by":"publisher","award":["NS003130"],"award-info":[{"award-number":["NS003130"]}],"id":[{"id":"10.13039\/100000065","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Hum Genet"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease that is universally fatal and has no cure. Heterogeneity of clinical presentation, disease onset, and proposed pathological mechanisms are key reasons why developing impactful therapies for ALS has been challenging. Here we analyzed data from two postmortem cohorts: one with bulk transcriptomes from 297 ALS patients and a separate cohort of single cell transcriptomes from 23 ALS patients. Using unsupervised machine learning, we found three groups of ALS patients characterized by synaptic dysfunction (34%), neuronal regeneration (47%), and neuronal degeneration (19%). Each of these ALS subtypes had unique patterns of transcriptional dysregulation that could represent novel therapeutic targets. We then developed a supervised machine learning model that was about 80% accurate at predicting ALS subtype based on patient demographic and clinical data. Together, we established three biologically distinct subtypes of ALS that can be predicted by clinical and demographic data.<\/jats:p>","DOI":"10.1038\/s41431-025-01920-y","type":"journal-article","created":{"date-parts":[[2025,8,7]],"date-time":"2025-08-07T10:03:28Z","timestamp":1754561008000},"page":"1290-1299","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Machine learning predicts distinct biotypes of amyotrophic lateral sclerosis"],"prefix":"10.1038","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4792-0405","authenticated-orcid":false,"given":"Nicholas","family":"Pasternack","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ole","family":"Paulsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0927-5855","authenticated-orcid":false,"given":"Avindra","family":"Nath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,7]]},"reference":[{"key":"1920_CR1","doi-asserted-by":"publisher","first-page":"171","DOI":"10.4103\/2152-7806.169561","volume":"6","author":"S Zarei","year":"2015","unstructured":"Zarei S, Carr K, Reiley L, Diaz K, Guerra O, Altamirano PF, et al. A comprehensive review of amyotrophic lateral sclerosis. Surg Neurol Int. 2015;6:171.","journal-title":"Surg Neurol Int"},{"key":"1920_CR2","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s13311-014-0332-8","volume":"12","author":"J Rosenfeld","year":"2015","unstructured":"Rosenfeld J, Strong MJ. Challenges in the understanding and treatment of amyotrophic lateral sclerosis\/motor neuron disease. Neurotherapeutics. 2015;12:317\u201325.","journal-title":"Neurotherapeutics"},{"key":"1920_CR3","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1002\/mus.26801","volume":"62","author":"NA Goyal","year":"2020","unstructured":"Goyal NA, Berry JD, Windebank A, Staff NP, Maragakis NJ, Berg LH, et al. Addressing heterogeneity in amyotrophic lateral sclerosis clinical trials. Muscle Nerve. 2020;62:156\u201366.","journal-title":"Muscle Nerve"},{"key":"1920_CR4","doi-asserted-by":"publisher","first-page":"1164","DOI":"10.1016\/j.celrep.2019.09.066","volume":"29","author":"OH Tam","year":"2019","unstructured":"Tam OH, Rozhkov NV, Shaw R, Kim D, Hubbard I, Fennessey S, et al. Postmortem cortex samples identify distinct molecular subtypes of ALS: retrotransposon activation, oxidative stress, and activated glia. Cell Rep. 2019;29:1164\u201377.","journal-title":"Cell Rep"},{"key":"1920_CR5","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1002\/ana.22149","volume":"69","author":"R Douville","year":"2011","unstructured":"Douville R, Liu J, Rothstein J, Nath A. Identification of active loci of a human endogenous retrovirus in neurons of patients with amyotrophic lateral sclerosis. Ann Neurol. 2011;69:141\u201351.","journal-title":"Ann Neurol"},{"key":"1920_CR6","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1007\/s13311-022-01233-8","volume":"19","author":"W Li","year":"2022","unstructured":"Li W, Pandya D, Pasternack N, Garcia-Montojo M, Henderson L, Kozak CA, et al. Retroviral elements in pathophysiology and as therapeutic targets for amyotrophic lateral sclerosis. Neurotherapeutics. 2022;19:1085\u2013101.","journal-title":"Neurotherapeutics"},{"key":"1920_CR7","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1002\/ana.26466","volume":"92","author":"M Garcia-Montojo","year":"2022","unstructured":"Garcia-Montojo M, Simula ER, Fathi S, McMahan C, Ghosal A, Berry JD, et al. Antibody response to HML-2 may be protective in amyotrophic lateral sclerosis. Ann Neurol. 2022;92:782\u201392.","journal-title":"Ann Neurol"},{"key":"1920_CR8","doi-asserted-by":"publisher","unstructured":"Li W, Lee MH, Henderson L, Tyagi R, Bachani M, Steiner J, et al. Human endogenous retrovirus-K contributes to motor neuron disease. Sci Transl Med. 2015. https:\/\/doi.org\/10.1126\/scitranslmed.aac8201.","DOI":"10.1126\/scitranslmed.aac8201"},{"key":"1920_CR9","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1002\/ana.26452","volume":"92","author":"JP Steiner","year":"2022","unstructured":"Steiner JP, Bachani M, Malik N, DeMarino C, Li W, Sampson K, et al. Human endogenous retrovirus K envelope in spinal fluid of amyotrophic lateral sclerosis is toxic. Ann Neurol. 2022;92:545\u201361.","journal-title":"Ann Neurol"},{"key":"1920_CR10","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2021.117358","volume":"423","author":"M Garcia-Montojo","year":"2021","unstructured":"Garcia-Montojo M, Fathi S, Norato G, Smith BR, Rowe DB, Kiernan MC, et al. Inhibition of HERV-K (HML-2) in amyotrophic lateral sclerosis patients on antiretroviral therapy. J Neurol Sci. 2021;423:117358.","journal-title":"J Neurol Sci"},{"key":"1920_CR11","doi-asserted-by":"crossref","unstructured":"Pineda SS, Lee H, Ulloa-Navas MJ, Linville RM, Garcia FJ, Galani K, et al. Single-cell profiling of the human primary motor cortex in ALS and FTLD. Cell. 2024;187:1971\u20131989.e16","DOI":"10.1016\/j.cell.2024.02.031"},{"key":"1920_CR12","doi-asserted-by":"publisher","unstructured":"Skene NG, Grant SGN. Identification of vulnerable cell types in major brain disorders using single cell transcriptomes and Expression Weighted Cell Type Enrichment. Front Neurosci. 2016. https:\/\/doi.org\/10.3389\/fnins.2016.00016.","DOI":"10.3389\/fnins.2016.00016"},{"key":"1920_CR13","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-35494-w","volume":"14","author":"J Eshima","year":"2023","unstructured":"Eshima J, O\u2019Connor SA, Marschall E, Bowser R, Plaisier CL, Smith BS. Molecular subtypes of ALS are associated with differences in patient prognosis. Nat Commun. 2023;14:95.","journal-title":"Nat Commun"},{"key":"1920_CR14","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1186\/s40478-023-01616-8","volume":"11","author":"O Aousji","year":"2023","unstructured":"Aousji O, Feldengut S, Antonucci S, Sch\u00f6n M, Boeckers TM, Matschke J, et al. Patterns of synaptic loss in human amyotrophic lateral sclerosis spinal cord: a clinicopathological study. Acta Neuropathol Commun. 2023;11:120.","journal-title":"Acta Neuropathol Commun"},{"key":"1920_CR15","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-37630-6","volume":"14","author":"OJ Ziff","year":"2023","unstructured":"Ziff OJ, Neeves J, Mitchell J, Tyzack G, Martinez-Ruiz C, Luisier R, et al. Integrated transcriptome landscape of ALS identifies genome instability linked to TDP-43 pathology. Nat Commun. 2023;14:2176.","journal-title":"Nat Commun"},{"key":"1920_CR16","doi-asserted-by":"publisher","first-page":"3770","DOI":"10.1093\/brain\/awad075","volume":"146","author":"A Catanese","year":"2023","unstructured":"Catanese A, Rajkumar S, Sommer D, Masrori P, Hersmus N, Van Damme P, et al. Multiomics and machine-learning identify novel transcriptional and mutational signatures in amyotrophic lateral sclerosis. Brain. 2023;146:3770\u201382.","journal-title":"Brain"},{"key":"1920_CR17","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1038\/s41593-022-01205-3","volume":"26","author":"J Humphrey","year":"2023","unstructured":"Humphrey J, Venkatesh S, Hasan R, Herb JT, de Paiva Lopes K, K\u00fc\u00e7\u00fckali F, et al. Integrative transcriptomic analysis of the amyotrophic lateral sclerosis spinal cord implicates glial activation and suggests new risk genes. Nat Neurosci. 2023;26:150\u201362.","journal-title":"Nat Neurosci"},{"key":"1920_CR18","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.3390\/biology11081191","volume":"11","author":"C Schweingruber","year":"2022","unstructured":"Schweingruber C, Hedlund E. The cell autonomous and non-cell autonomous aspects of neuronal vulnerability and resilience in amyotrophic lateral sclerosis. Biology. 2022;11:1191.","journal-title":"Biology"},{"key":"1920_CR19","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1007\/s00401-017-1708-8","volume":"133","author":"J Nijssen","year":"2017","unstructured":"Nijssen J, Comley LH, Hedlund E. Motor neuron vulnerability and resistance in amyotrophic lateral sclerosis. Acta Neuropathol. 2017;133:863\u201385.","journal-title":"Acta Neuropathol"},{"key":"1920_CR20","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/0022-510X(82)90173-3","volume":"55","author":"N Hanyu","year":"1982","unstructured":"Hanyu N, Oguchi K, Yanagisawa N, Tsukagoshi H. Degeneration and regeneration of ventral root motor fibers in amyotrophic lateral sclerosis. J Neurol Sci. 1982;55:99\u2013115.","journal-title":"J Neurol Sci"},{"key":"1920_CR21","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-31720-7","volume":"13","author":"KL Marshall","year":"2023","unstructured":"Marshall KL, Rajbhandari L, Venkatesan A, Maragakis NJ, Farah MH. Enhanced axonal regeneration of ALS patient iPSC-derived motor neurons harboring SOD1A4V mutation. Sci Rep. 2023;13:5597.","journal-title":"Sci Rep"},{"key":"1920_CR22","doi-asserted-by":"publisher","unstructured":"Pradhan J, Noakes PG, Bellingham MC. The role of altered BDNF\/TrkB signaling in amyotrophic lateral sclerosis. Front Cell Neurosci. 2019. https:\/\/doi.org\/10.3389\/fncel.2019.00368.","DOI":"10.3389\/fncel.2019.00368"},{"key":"1920_CR23","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.nbd.2006.12.023","volume":"26","author":"M Dewil","year":"2007","unstructured":"Dewil M, dela Cruz VF, Van Den Bosch L, Robberecht W. Inhibition of p38 mitogen activated protein kinase activation and mutant SOD1G93A-induced motor neuron death. Neurobiol Dis. 2007;26:332\u201341.","journal-title":"Neurobiol Dis"},{"key":"1920_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41419-018-0624-8","volume":"9","author":"KL Gibbs","year":"2018","unstructured":"Gibbs KL, Kalmar B, Rhymes ER, Fellows AD, Ahmed M, Whiting P, et al. Inhibiting p38 MAPK alpha rescues axonal retrograde transport defects in a mouse model of ALS. Cell Death Dis. 2018;9:596.","journal-title":"Cell Death Dis"},{"key":"1920_CR25","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1111\/bpa.12485","volume":"28","author":"CJHM Klemann","year":"2018","unstructured":"Klemann CJHM, Visser JE, Van Den Bosch L, Martens GJM, Poelmans G. Integrated molecular landscape of amyotrophic lateral sclerosis provides insights into disease etiology. Brain Pathol. 2018;28:203\u201311.","journal-title":"Brain Pathol"},{"key":"1920_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2022.110913","volume":"39","author":"M Czuppa","year":"2022","unstructured":"Czuppa M, Dhingra A, Zhou Q, Schludi C, K\u00f6nig L, Scharf E, et al. Drug screen in iPSC-Neurons identifies nucleoside analogs as inhibitors of (G4C2)n expression in C9orf72 ALS\/FTD. Cell Rep. 2022;39:110913.","journal-title":"Cell Rep"},{"key":"1920_CR27","doi-asserted-by":"publisher","first-page":"4291","DOI":"10.3390\/ijms21124291","volume":"21","author":"M Galbiati","year":"2020","unstructured":"Galbiati M, Crippa V, Rusmini P, Cristofani R, Messi E, Piccolella M, et al. Multiple roles of transforming growth factor beta in amyotrophic lateral sclerosis. Int J Mol Sci. 2020;21:4291.","journal-title":"Int J Mol Sci"},{"key":"1920_CR28","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1001\/jamaneurol.2014.3367","volume":"72","author":"F-C Lin","year":"2015","unstructured":"Lin F-C, Tsai C-P, Kuang-Wu Lee J, Wu M-T, Tzu-Chi Lee C. Angiotensin-converting enzyme inhibitors and amyotrophic lateral sclerosis risk. JAMA Neurol. 2015;72:40.","journal-title":"JAMA Neurol"},{"key":"1920_CR29","doi-asserted-by":"publisher","first-page":"7339","DOI":"10.3390\/ijms21197339","volume":"21","author":"M Rodr\u00edguez-Mu\u00f1oz","year":"2020","unstructured":"Rodr\u00edguez-Mu\u00f1oz M, Cort\u00e9s-Montero E, Garz\u00f3n-Ni\u00f1o J, S\u00e1nchez-Bl\u00e1zquez P. The ALS-related \u03c31R E102Q mutant eludes ligand control and exhibits anomalous response to calcium. Int J Mol Sci. 2020;21:7339.","journal-title":"Int J Mol Sci"},{"key":"1920_CR30","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.jphs.2014.12.013","volume":"127","author":"TA Mavlyutov","year":"2015","unstructured":"Mavlyutov TA, Guo L-W, Epstein ML, Ruoho AE. Role of the Sigma-1 receptor in amyotrophic lateral sclerosis (ALS). J Pharm Sci. 2015;127:10\u201316.","journal-title":"J Pharm Sci"},{"key":"1920_CR31","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1007\/s13311-012-0140-y","volume":"9","author":"R Mancuso","year":"2012","unstructured":"Mancuso R, Oliv\u00e1n S, Rando A, Casas C, Osta R, Navarro X. Sigma-1R agonist improves motor function and motoneuron survival in ALS mice. Neurotherapeutics. 2012;9:814\u201326.","journal-title":"Neurotherapeutics"},{"key":"1920_CR32","doi-asserted-by":"crossref","unstructured":"Ingre C, Roos P, Piehl F, Kamel F, Fang F. Risk factors for amyotrophic lateral sclerosis. Clin Epidemiol. 2015;7:181\u201393.","DOI":"10.2147\/CLEP.S37505"},{"key":"1920_CR33","doi-asserted-by":"publisher","first-page":"65","DOI":"10.3109\/21678421.2014.971813","volume":"16","author":"L Rechtman","year":"2015","unstructured":"Rechtman L, Jordan H, Wagner L, Horton DK, Kaye W. Racial and ethnic differences among amyotrophic lateral sclerosis cases in the United States. Amyotroph Lateral Scler Frontotemporal Degener. 2015;16:65\u201371.","journal-title":"Amyotroph Lateral Scler Frontotemporal Degener"},{"key":"1920_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.110147","volume":"27","author":"N Pasternack","year":"2024","unstructured":"Pasternack N, Doucet-O\u2019Hare T, Johnson K, Paulsen O, Nath A. Endogenous retroviruses are dysregulated in ALS. iScience. 2024;27:110147.","journal-title":"iScience"},{"key":"1920_CR35","doi-asserted-by":"publisher","first-page":"3593","DOI":"10.1093\/bioinformatics\/btv422","volume":"31","author":"Y Jin","year":"2015","unstructured":"Jin Y, Tam OH, Paniagua E, Hammell M. TEtranscripts: a package for including transposable elements in differential expression analysis of RNA-seq datasets. Bioinformatics. 2015;31:3593\u20139.","journal-title":"Bioinformatics"},{"key":"1920_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-18416-6","volume":"11","author":"S Mohammadi","year":"2020","unstructured":"Mohammadi S, Davila-Velderrain J, Kellis M. A multiresolution framework to characterize single-cell state landscapes. Nat Commun. 2020;11:5399.","journal-title":"Nat Commun"}],"container-title":["European Journal of Human Genetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41431-025-01920-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41431-025-01920-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41431-025-01920-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T09:25:45Z","timestamp":1759137945000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41431-025-01920-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,7]]},"references-count":36,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["1920"],"URL":"https:\/\/doi.org\/10.1038\/s41431-025-01920-y","relation":{},"ISSN":["1018-4813","1476-5438"],"issn-type":[{"value":"1018-4813","type":"print"},{"value":"1476-5438","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,7]]},"assertion":[{"value":"8 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 July 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All methods were carried out in accordance with, and were approved by, the appropriate institutions. All samples and data were acquired at the Neuropathology Laboratory at the Mayo Clinic in Jacksonville, FL, or by the NYGC ALS Consortium, a multi-institution consortium. All data are derived from post-mortem samples which were acquired with the appropriate informed consents and relevant IRB protocols from the corresponding member sites. A full list of member institutions of the NYGC is available in the supplement.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}